SERPINE1 and Obesity: Tiplaxtinin, the most well studied low molecular weight inhibitor of PAI-1 has also been shown to attenuate asthmatic flare-ups, obesity, diabetes, cancer cell motility and angiogenesis in various studies, is the only low molecular weight antagonist of PAI-1 discussed here to be studied in a restenotic animal model [88-95].